Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2021

View Archived Issues

BioNTech initiates first-in-human study of BNT-151

First-in-human data for ACT-1004-1239

QBW-251 enters phase II for bronchiectasis

NLY-01 exerts neuroprotective effects in model of experimental autoimmune encephalomyelitis

Enrollment opens in phase II study of RO-7017773 for autism spectrum disorder

Diverse populations, long reads give genome insights

Promising interim data presented from SAD portion of MORF-057 phase I program

VBL Therapeutics initiates dosing patients in phase II study of VB-111 in rGBM

Anti-TNF-alpha antibodies presented by Sinocelltech

Bristol Myers Squibb presents new ROR-gammaT agonists

Amgen discovers kinesin-like protein KIF18A inhibitors

Alkermes patents mu-opioid receptor agonists

New Janus kinase inhibitors synthesized at Vimalan Biosciences

New bispecifics capture challenging targets

FDA clears IND application for FX-301 for postoperative pain

Alofanib shows safety and antitumor efficacy in patients with advanced gastric cancer

Myoferlin inhibitor YQ-456 shows efficacy in PDX model of colorectal cancer

FDA agrees to advance VERU-111 into phase III study in COVID-19 patients at high risk for ARDS

FDA issues complete response letter for oral paclitaxel plus encequidar in metastatic breast cancer

First patient dosed in phase II study of OTX-DED for short-term treatment of dry eye disease

Inovio reports phase III data on VGX-3100 to treat HPV-16/18 cervical HSIL

MEDI-1191 demonstrates preliminary antitumor activity in advanced solid tumors

Carna receives CTA clearance for phase I study of BTK inhibitor AS-1763

ADORA2A is a therapeutic target in progressive multiple sclerosis

Merck & Co. withdraws U.S. indication for Keytruda in metastatic SCLC after platinum chemotherapy

Hoth advances site recruitment for first-in-human study of BioLexa for atopic dermatitis

Kymera begins dosing in first-in-human study of KT-474 for atopic dermatitis or HS